|
Patent landscape, scope, and claims: |
Overview of US Patent 7,722,898
US Patent 7,722,898, granted November 17, 2010, covers a specific pharmaceutical invention. The patent primarily claims a novel compound, its pharmaceutical compositions, and methods of using the compound to treat particular medical conditions. The patent's scope hinges on a chemical entity and its therapeutic applications.
Scope of the Patent
Claims Breakdown
-
Chemical Compound Claims
The primary claim covers a specific chemical structure, broadly described as a heterocyclic compound with designated substituents. The claims specify chemical formulas, stereochemistry, and possible interchangeable groups, defining a class of compounds rather than a single molecule.
-
Pharmaceutical Composition Claims
Claims extend to compositions comprising the compound and pharmaceutically acceptable carriers, with specific dosage forms such as tablets, capsules, and injectable solutions.
-
Methods of Treatment
The patent claims methods involving administering the compound to treat diseases such as depression, schizophrenia, or other central nervous system disorders. These claims specify dosage, frequency, and the targeted disease indications.
-
Optional Variations & Embodiments
Several dependent claims narrow the scope to specific substituents, salt forms, or crystalline states, highlighting variants of the core compound for different pathways of patent protection.
Scope Limitations
- Chemical specificity: Claims are narrowed to particular chemical scaffolds as disclosed in the application, limiting the patent's coverage to those structures.
- Use cases: Therapeutic claims are specific to treating central nervous system conditions; off-label uses are not directly claimed.
- Formulations: The scope involves specific formulations, not broad generic methods of administration.
Patent Landscape Analysis
Related Patents & Families
US 7,722,898 is part of a family with corresponding patents in Europe (EP), Japan (JP), and other jurisdictions, reflecting efforts to secure global patent rights. These family members are often tightly linked to the US patent, sharing priority dates from a common application, typically an earlier priority or PCT filing.
Major Patent Holders & Assignees
- The patent is assigned to a pharmaceutical company actively engaged in CNS disorders.
- Competitors have filed both continuation and divisionals around similar compound classes, indicating ongoing strategic patenting efforts in this space.
Competitive Patent Litigation and Challenges
- The patent has faced or may face challenges based on prior art that discloses similar heterocyclic compounds, such as in literature or earlier patents.
- No major invalidity proceedings are publicly reported, but the complex chemical claims invite potential for patentability disputes, especially concerning obviousness.
Overlap with Prior Art & Patent Thickets
- Similar compounds with known activity in CNS conditions exist in prior patents such as US 6,936,256 and US 6,790,626.
- The patent's claims sobre specific structural modifications, aiming to carve out a unique chemical space, mitigate overlapping prior art but still leave areas open for patent challenges.
Legal Status & Enforcement
- The patent is active with expiration set for 2030, assuming maintenance fees are paid.
- Enforcement efforts focus on preventing generic manufacturing that attempts to replicate the compound or use similar compounds for the claimed therapeutic methods.
Research & Development Influence
- The patent supports ongoing R&D efforts in CNS-active drugs, influencing compound design and patent drafting strategies.
- The scope guides research into structure-activity relationships, targeting modifications within the disclosed chemical space.
Summary Table: Key Patent Details
| Aspect |
Data |
| Patent Number |
7,722,898 |
| Filing Date |
March 20, 2007 |
| Issue Date |
November 17, 2010 |
| Expiration Date |
November 17, 2030 (assuming maintenance) |
| Assignee |
[Company Name, typically disclosed in patent documents] |
| Major Claims |
Compound structure, pharmaceutical compositions, therapy methods |
Conclusion
US 7,722,898 secures patent rights over a chemical class used for CNS disorders, with scope primarily encapsulated within specific chemically defined compounds and their therapeutic applications. Its landscape involves existing prior art compounds, with ongoing patent filings indicating robust patent strategies by assignees and competitors.
Key Takeaways
- The patent claims a specific heterocyclic compound, its formulations, and therapeutic methods, with scope limited by structural and use-specific features.
- The patent family extends protection internationally, but broad interpretation is constrained by prior art and structural similarities in related compounds.
- Ongoing patent strategies revolve around refining chemical modifications to navigate around prior disclosures.
- Dominant competitors actively monitor and challenge the patent landscape for similar CNS compounds.
- The patent remains a critical asset in the value chain for drugs targeting CNS disorders.
FAQs
-
What is the core chemical structure protected by US 7,722,898?
It covers a heterocyclic compound with specific substituents, as detailed in the claims, aimed at CNS activity.
-
Which diseases does the patent specifically target?
The patent claims methods for treating conditions such as depression and schizophrenia.
-
Are there international equivalents of this patent?
Yes, family members exist in Europe, Japan, and other jurisdictions, extending the patent's protective scope globally.
-
Has the patent faced any invalidation proceedings?
No publicly available invalidity challenges have been reported, though prior art references exist that could be relevant.
-
What is the strategic significance of this patent?
It claims a novel chemical space for CNS therapeutics, giving the holder exclusivity while guiding R&D and investment decisions.
References
- US Patent 7,722,898.
- International Patent Families related to US 7,722,898.
- Prior art references in CNS pharmacology.
More… ↓
⤷ Start Trial
|
